Posted by Michael Wonder on 07 Jan 2020
Antibiotics need a special place in the drug pricing debate
7 January 2020 - Melinta Therapeutics, one of the few companies to recently bring a new antibiotic to market, filed for bankruptcy at the end of December.
This news comes less than a year after another antibiotic developer, Achaogen, did the same thing.
More than 90% of antibiotics in the pipeline today are being developed by small companies like these, not by the pharmaceutical giants that once dominated the field. And with antibiotic prices low and profit margins narrow, many small companies just can’t stay afloat.
